Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025
Vaxart (NASDAQ: VXRT), a clinical-stage biotech company specializing in oral recombinant pill vaccines, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management team will engage in a fireside chat on June 5, 2025, at 2:00 PM ET. The event will be accessible via live webcast on Vaxart's website, with a replay available for 30 days after the event. Investors seeking meetings with management during the conference should contact their Jefferies representative.
Vaxart (NASDAQ: VXRT), un'azienda biotecnologica in fase clinica specializzata in vaccini ricombinanti orali in forma di pillola, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. Il team di gestione dell'azienda parteciperà a una conversazione informale il 5 giugno 2025, alle 14:00 ET. L'evento sarà disponibile tramite webcast in diretta sul sito web di Vaxart, con una replica accessibile per 30 giorni dopo l'evento. Gli investitori interessati a incontri con il management durante la conferenza dovrebbero contattare il loro rappresentante Jefferies.
Vaxart (NASDAQ: VXRT), una empresa biotecnológica en etapa clínica especializada en vacunas recombinantes orales en forma de pastilla, ha anunciado su participación en la próxima Jefferies Global Healthcare Conference. El equipo directivo de la empresa participará en una charla informal el 5 de junio de 2025, a las 2:00 PM ET. El evento será accesible mediante una transmisión en vivo en el sitio web de Vaxart, con una repetición disponible durante 30 días después del evento. Los inversores que deseen reunirse con la dirección durante la conferencia deben contactar a su representante de Jefferies.
Vaxart (NASDAQ: VXRT)는 경구용 재조합 필 백신을 전문으로 하는 임상 단계의 바이오테크 회사로, 다가오는 Jefferies Global Healthcare Conference에 참여할 것이라고 발표했습니다. 회사 경영진은 2025년 6월 5일 오후 2시(동부시간)에 파이어사이드 채팅에 참여할 예정입니다. 이 행사는 Vaxart 웹사이트를 통해 생중계되며, 행사 종료 후 30일 동안 다시보기 서비스를 제공합니다. 회의 기간 동안 경영진과의 미팅을 원하는 투자자는 자신의 Jefferies 담당자에게 연락해야 합니다.
Vaxart (NASDAQ : VXRT), une société biotechnologique en phase clinique spécialisée dans les vaccins recombinants oraux sous forme de pilule, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. L'équipe de direction de l'entreprise participera à une discussion informelle le 5 juin 2025 à 14h00 ET. L'événement sera accessible via un webcast en direct sur le site web de Vaxart, avec une rediffusion disponible pendant 30 jours après l'événement. Les investisseurs souhaitant organiser des rencontres avec la direction pendant la conférence doivent contacter leur représentant Jefferies.
Vaxart (NASDAQ: VXRT), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf orale rekombinante Pillenimpfstoffe spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference angekündigt. Das Management-Team des Unternehmens wird am 5. Juni 2025 um 14:00 Uhr ET an einem Fireside-Chat teilnehmen. Die Veranstaltung wird live per Webcast auf der Website von Vaxart zugänglich sein, mit einer Wiederholung, die 30 Tage nach der Veranstaltung verfügbar ist. Investoren, die während der Konferenz Treffen mit dem Management wünschen, sollten ihren Jefferies-Vertreter kontaktieren.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that members of the management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 2:00 PM ET.
A live webcast of the fireside chat will be available on the Company’s website at www.vaxart.com or by clicking here. A replay of the fireside chat will be available for 30 days following the conclusion of the event.
Investors interested in meeting with management during the conference may reach out to their Jefferies representative.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
| Vaxart Media and Investor Relations: |
| Matt Steinberg |
| FINN Partners |
| IR@vaxart.com |
| (646) 871-8481 |
This press release was published by a CLEAR® Verified individual.
FAQ
When is Vaxart (VXRT) presenting at the Jefferies Global Healthcare Conference 2025?
How can investors watch Vaxart's (VXRT) presentation at the Jefferies Healthcare Conference?
What does Vaxart (VXRT) specialize in as a company?
How can investors meet with Vaxart's management at the Jefferies Conference?
